Skip to content
To the full analysis

Privia Health Group stock: balance sheet and debt

PRVA
$23.67Closing price of 12 Nov 2026MEQIRI Score 57 out of 100

Privia Health Group has a debt to equity ratio of 0.01 and an interest coverage of over 100x.

Daily figure as of 13 Nov 2026

Debt / Equity
0.01
Interest coverage
> 100x
Current ratio
1.6
Cash & equivalents
$479.69M
Total assets
$1.37B
Equity ratio
57.8%
Goodwill
$209.84M
Plus intangible assets of $215.92M
Net debt
−$470.15M
More cash than debt

Total assets and equity ratio

How large the balance sheet of Privia Health Group, Inc. is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2018$249.49M$125.93M$118.66M34.5%$27.9M
2019$270.21M$125.29M$118.66M39.8%−$3.79M
2020$328.97M$124.64M$118.66M43.7%−$50.97M
2021$686.37M$187.68M$127.94M65.6%−$274.08M
2022$792.81M$184.33M$126.94M65.5%−$336.49M
2023$999.9M$246.38M$138.75M60.7%−$381.22M
2024$1.14B$251.42M$141.62M60.2%−$485.56M
2025$1.37B$425.76M$209.84M57.8%−$470.15M

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2018$39.11M$88.5M$67M0.78
2019$46.89M$110.21M$43.1M0.4
2020$84.63M$146.75M$33.66M0.23
2021$320.58M$426.87M$46.5M0.1
2022$347.99M$499.09M$11.5M0.02
2023$389.51M$561.44M$8.29M0.01
2024$491.15M$635.18M$5.59M0.01
2025$479.69M$737.22M$9.53M0.01

Debt to equity divides debt by total equity, including non-controlling interests, as S&P calculates it. The equity column shows the part that belongs to shareholders.

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Neutral, published since 7 Nov 2026 (in the score history since 5 Nov 2026)
  • Valuation signal Fairly valued since 12 Nov 2026, previously Overvalued
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy